Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma

Table 2

The clinical results for the two groups.

Response	Number of patients (%)
	Group 1 ()	Group 2 ()	Total ()
CR	15 (30.6%)	5 (25%)	20 (29.0%)
PR	17 (34.7%)	8 (40%)	25 (36.2%)
ORR (CR + PR)	32 (65.3%)	13 (65%)	45 (65.2%)
SD	8 (16.3%)	3 (15%)	11 (15.9%)
PD	9 (18.4%)	4 (20%)	13 (18.9%)

CR: complete response, PR: partial response, ORR: overall response rate, SD: stable disease, and PD: progressive disease.